C4 Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders using its TORPEDO platform. It has no approved products and has generated no product-sales revenue.
Financial results and position
| Metric | Q3 2022 | Q3 2021 | First nine months 2022 | First nine months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $6.8 million | $8.5 million | $28.2 million | $25.7 million |
| Research and development expense | $29.7 million | $24.3 million | $87.2 million | $68.1 million |
| General and administrative expense | $9.6 million | $8.5 million | $32.3 million | $24.5 million |
| Operating loss | $32.5 million | $24.3 million | $91.2 million | $66.9 million |
| Net loss | $32.0 million | $24.7 million | $91.0 million | $68.2 million |
| Basic and diluted loss per share | $0.65 | $0.51 | $1.86 | $1.51 |
Margins: The filing presents collaboration revenue and operating expenses, not product gross profit; a gross margin is therefore not meaningful from the disclosed figures. Operating loss was greater than collaboration revenue in both periods.
Liquidity and debt: At September 30, 2022, cash and cash equivalents were $49.6 million and marketable securities totaled $316.5 million, or approximately $366.0 million combined. Current assets were $325.5 million and current liabilities were $45.3 million. The company reported $11.3 million of long-term debt, net of discount and issuance costs, owed to related party Perceptive; the loan bears interest at 12.07%, is secured by substantially all assets, and matures June 2024. Operating lease liabilities totaled $76.8 million.
Cash flow, first nine months: Operating activities used $76.8 million, compared with $61.3 million in 2021. Investing activities provided $49.1 million, principally reflecting maturities of marketable securities net of purchases, while financing activities provided $1.1 million. Cash, cash equivalents and restricted cash decreased by $26.6 million.
Changes versus the prior comparable period
- Q3 collaboration revenue declined $1.7 million year over year, primarily because Roche revenue fell after the BRAF target was terminated from that collaboration in November 2021.
- Nine-month collaboration revenue increased $2.5 million, mainly from progress under the Biogen agreement; this was partly offset by lower Calico reimbursements and lower Roche revenue.
- Nine-month R&D expense increased $19.1 million, reflecting higher personnel, clinical-trial and facility costs. G&A expense increased $7.8 million, primarily from personnel costs.
- Nine-month net loss widened by $22.8 million. Interest and other income improved, but did not offset higher operating expenses.
- Accumulated other comprehensive loss from unrealized marketable-security losses reached $5.4 million, compared with $0.8 million at December 31, 2021.
Outlook, commentary and risks
- Management expects ongoing operating losses and substantially higher R&D expenses as programs advance. The filing states in the financial-statement notes that cash, cash equivalents and marketable securities are expected to fund operations for at least 12 months from issuance; elsewhere, the risk-factor discussion says those resources plus expected collaboration payments are expected to fund the existing operating plan through the end of 2024. Management cautions that the estimate depends on assumptions and capital could be depleted sooner.
- Pipeline update: CFT7455 and CFT8634 were in Phase 1/2 trials; CFT1946 had received an FDA Study May Proceed letter, with trial initiation expected by year-end 2022; CFT8919 IND-enabling work was expected to be completed by year-end 2022.
- The company reported toxicity in patients in Cohort A of the CFT7455 trial and modified dosing for subsequent cohorts. It noted that early clinical findings may not predict later results.
- Key risks include clinical and regulatory failure or delays, patient enrollment, manufacturing and supplier dependence, competition, intellectual-property protection, collaboration-partner decisions, COVID-19-related disruption, and the need for additional financing. Existing collaborations may produce future milestones or royalties, but none are committed external funding.
- Marketable securities were exposed to interest-rate risk; their weighted-average maturity was 0.8 years. The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Reconcile the stated cash runway: at least 12 months from financial-statement issuance versus funding through year-end 2024 when expected collaboration payments are included; review the underlying assumptions and planned spending.
- Check subsequent clinical disclosures for CFT7455 dosing, safety, enrollment and efficacy, and for progress against CFT8634, CFT1946 and CFT8919 timelines.
- Assess cash burn and whether collaboration revenue, milestone receipts or new financing can support the development plan; the company says substantial additional funding will be needed to take candidates through approval.
- Review debt service and covenant exposure, including the secured loan’s variable interest rate, $3.0 million minimum controlled-account balance and June 2024 maturity.
- Track collaboration-program status and partner decisions, since reported revenue is collaboration-based and future milestones and royalties depend on further development and commercialization.